36. The composition according to claim 32, wherein the microparticle consists of a biodegradable polymer.

37. The composition according to claim 36, wherein the polymer is selected from the group consisting of a lactide-containing polymer, a glycolide-containing polymer and a polymer comprising lactide and glycolide.

38. The composition according to claim 32, wherein the microparticle is in the size range 0.1 μm to 10 μm.

39. The composition according to claim 32, wherein the DNA is circular DNA or plasmid DNA.

40. The composition according to claim 32, wherein the DNA further comprises a promoter sequence operably linked to the coding sequence.

41. The composition according to claim 40, wherein the coding sequence encodes an immunogen.

42. The composition according to claim 41, wherein the coding sequence encodes an immunogenic component of a pathogenic organism selected from the group consisting of pathogenic bacteria and pathogenic viruses.

43. A pharmaceutical composition comprising a plurality of polymer microparticles and a pharmaceutically acceptable carrier, wherein the microparticles contain an aqueous solution of DNA, the aqueous solution of DNA has an alcohol content of 1 to 40%, and the DNA comprises a coding sequence encoding a polypeptide selected from the group consisting of:

(a) antigens FHA, PT, 68kd-Pertacin, tetanus toxin, gp-48, NS1, Capsid, gp350, NS3, SA, I, NP, E, M, gp340, F, H, HN, 35kd protein, BP1, E1, E2, C, M, E and MSHA; and

(b) immunogenic fragments of the polypeptides of (a).

44. The composition according to claim 43 wherein the micropartices are in the size range 0.1 μm to 10 μm.

45. The composition according to claim 44, wherein the DNA comprises double stranded plasmid DNA.

46. The composition according to claim 45, wherein the DNA further comprises a promoter sequence operably linked to the coding sequence.

47. The composition according to claim 43, wherein the polymer is a lactide containing polymer.

48. The composition according to claim 43, wherein the polymer is a glycolide-containing polymer.

49. The composition according to claim 43, wherein the polymer comprises poly(DL-lactide-co-glycolide).

50. The composition according to claim 43 wherein at least 50% of the microparticles are in the size range 0.1 μm to 10 μm.

51. The composition according to claim 43, further comprising a taste-enhancing agent.

52. A composition comprising a first and a second plurality of microparticles, wherein the first plurality of microparticles comprise (a) a first polymer having a first half-life *in vivo*, and (b) a first DNA comprising a sequence encoding a first immunogen, and the second plurality of microparticles comprise (i) a second polymer having a second half-life *in vivo*, and (ii) a second DNA comprising a sequence encoding a second immunogen.

53. The composition of claim 52, wherein the first and second immunogens are the same.

54. A composition according to claim 52, wherein the first half-life is up to two weeks and the second half-life is more than two weeks.

55. The composition of claim 52, wherein the first half-life of is up to two days and the second half life is more than two weeks.

56. The composition of claim 32, wherein the composition has a water content of less than 5%.--